Dengvaxia (Dengue vaccine) / Sanofi - LARVOL DELTA

Targeting Dendritic Cells with Virus-like Particles: Toward Safer and More Immunogenic Vaccines. (PubMed, Vaccines (Basel)) - "The newer "Qdenga" vaccine offers up to 80% efficacy after a year but provides suboptimal protection against DENV-3 in seronegative individuals... The administration of tetravalent dengue VLP vaccine in BALB/c mice did not result in adverse effects in acute or chronic toxicity evaluations. Therefore, the VLP supports progression toward clinical evaluation, with dendritic cell activation providing additional rationale."

Journal • Dengue Fever • Hematological Disorders

Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data. (PubMed, Virol J) - "This review provides a systematic review of the dengue vaccines data available from the last five years highlighting significant progress in vaccine development, efficacy, and safety and TAK-003 showed the greatest efficacy against hospitalized and symptomatic Dengue patients, reducing risk by 85% (RR 0.15; 95% CI 0.07-0.33)."

Journal • Review • Dengue Fever • Infectious Disease

Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial. (PubMed, Hum Vaccin Immunother) - P2 | "None of the participants discontinued the study due to an AE, and no deaths were reported. CYD-TDV demonstrated adequate safety and robust immunogenicity against all dengue serotypes in HIV-positive adults receiving prior antiretroviral treatment."

Journal • P2 data • Dengue Fever • Human Immunodeficiency Virus • Infectious Disease • Pain

Global epidemiology of dengue in paediatric and adolescent populations: a systematic review and meta-analysis. (PubMed, Infect Dis (Lond)) - "Dengue infection affects youth globally across all endemic regions, with similar incidence distribution among continents. These findings illuminate the global and country-specific dengue epidemiology, emphasising the need for enhanced mitigation measures to reduce viral spread and impact."

Journal • Retrospective data • Dengue Fever • Infectious Disease • Pediatrics

Assessing the impact of vaccination against dengue viruses using long-term antibody measurements (ASTMH 2025) - "The results suggest that the vaccine's protection is skewed towards a single dominant serotype, and this protection is of shorter duration compared to natural infection. These preliminary findings align with previous evidence suggesting that Dengvaxia's effectiveness may be limited by immunodominance and interference."

Dengue Fever • Infectious Disease

Challenges in the Prevention and Treatment of Dengue Fever: An Emerging Issue. (PubMed, Am J Trop Med Hyg) - "Existing vaccines, such as Dengvaxia® (Sanofi Pasteur, Paris, France) and Qdenga® (Takeda Pharmaceutical Company, Tokyo, Japan), have demonstrated some efficacy; however, limitations include a lack of efficacy against certain regional DENV strains and the potential for antibody-dependent enhancement (ADE), particularly in individuals without previous DENV exposure...The intricate pathogenesis of DENV, involving complex virus-host interactions and immune responses, presents additional treatment challenges. In this review, the current challenges and advancements in DF prevention and treatment are examined, emphasizing the limits of existing vaccines and medicines while exploring novel approaches with potential for effectiveness in clinical settings."

Journal • Dengue Fever

Structural and energetic basis of marine phytochemicals as dengue NS1 protein inhibitors. (PubMed, Sci Rep) - "It may suppress DENV proliferation. QSAR study suggested that this chemical is anti-viral, although in vivo and in vitro testing is needed."

Journal • Dengue Fever • Infectious Disease

Pathophysiology and clinical implications of dengue-associated neurological disorders. (PubMed, Front Microbiol) - "Although there are still challenges in reaching the ideal vaccination coverage, the introduction of potent vaccines like Dengvaxia and Qdenga provide an achievable option for prevention. Thorough study into DENV's neurological effects and treatment options is essential as the virus's geographic range is increased by climate change and international travel. Reducing the worldwide burden of dengue-related neurological complications requires addressing the intricate interactions between virological, immunological, and environmental variables."

Journal • Review • CNS Disorders • Dengue Fever • Infectious Disease • Inflammation • Multiple Sclerosis • Pain

Afucosylation of anti-dengue IgG is associated with enhanced susceptibility to dengue virus infection postvaccination. (PubMed, Sci Transl Med) - "Together, these findings support a model in which the presence of afucosylated IgG promotes virus replication, increasing the likelihood of productive infection upon DENV exposure. Moreover, these results highlight that IgG1 fucosylation is a predictor of risk for breakthrough DENV infection despite vaccination and support the importance of investigating strategies to regulate Fc fucosylation during vaccination."

Journal • Dengue Fever • Infectious Disease

State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature. (PubMed, Infect Dis Rep) - "Vaccines were categorized into licensed (CYD-TDV and TAK-003), late-stage (TV003/TV005), and early-stage candidates (TDEN, DPIV, V180, TVDV)...TAK-003 (Qdenga®) demonstrated high efficacy against virologically confirmed dengue (VCD) and dengue-related hospitalization...Currently, TAK-003 is regarded as the best option for broad implementation, while TV003 and TV005 remain promising candidates due to their shorter schedule and robust immunogenicity. Further research is needed to optimize vaccine strategies in seronegative populations, immunocompromised subjects, older adults, and travelers."

Journal • Review • Dengue Fever • Infectious Disease

A retrospective computational validation of a clinically evaluated recombinant envelope protein tetravalent dengue vaccine. (PubMed, Int J Biol Macromol) - "Licensed vaccines like Dengvaxia and Qdenga rely on yellow fever virus (YFV)-based vectors encoding DENV structural proteins, though ADE risks persist. However, limitations in predictive accuracy were noted, such as the erroneous docking of EDE1-C10 to EDIII, highlighting the need for improved modeling approaches incorporating structural dynamics and artificial intelligence (AI) tools. These results support further development of V180 and r2ED, while emphasizing the strengths and boundaries of computational vaccinology."

Journal • Retrospective data • Dengue Fever • Infectious Disease • CD8

Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection. (PubMed, Pediatr Investig) - "This review provides a comprehensive analysis of the historical and current landscape of dengue vaccine development, focusing on CYD-TDV, TAK-003, and Butantan-DV...Additionally, this review highlights key areas for future research, including the impact of ADE, advancements in vaccine platforms, the need for region-specific vaccine formulations, and the integration of vaccination into broader dengue prevention strategies. Ultimately, sustained investment and global collaboration are crucial for achieving the goal of a dengue-free world."

Journal • Review • Dengue Fever

The pre- and post-COVID-19 pandemic dengue fever patterns in southeastern coastal China in 2019 and 2024: molecular evolution and strain replacement. (PubMed, Front Microbiol) - "Complete genotype turnover of DENV-1 occurred in southeastern coastal China between 2019 and 2024, driven by displacement of lineage 1I_E.1 by 1I_K.2, with implications for local transmission patterns. Observed antigenic divergence between temporal isolates emphasizes the importance of sustained genomic monitoring and targeted intervention strategies tailored to circulating strains in this region."

Journal • Dengue Fever • Infectious Disease • Novel Coronavirus Disease

CYD00082: Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia (clinicaltrials.gov) - P=N/A | N=918 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Trial completion date: Jan 2030 ➔ Jul 2028 | Trial primary completion date: Jan 2030 ➔ Jul 2028

Trial completion date • Trial primary completion date • Dengue Fever

Dengue Vaccines. (PubMed, Curr Top Microbiol Immunol) - "The chapter reviews the historical trajectory and current landscape of vaccine candidates, such as Dengvaxia®, Qdenga®, and Butantan-DV, analyzing their efficacy, safety profiles, and the lessons learned from their clinical trials. It also discusses other hurdles like suitable animal models and viral interference. Ultimately, the chapter highlights the advancements made and outlines future research directions crucial for a universally effective dengue vaccine."

Journal • Dengue Fever

Medical knowledge, political tension, and social relevance: a content and framing analysis of vaccine-related TV broadcasts in the Philippines. (PubMed, BMJ Public Health) - "Training health professionals to emphasise under-represented information and to purposively engage with prominent message frames could improve vaccination communication. Beyond vaccine hesitancy, our results also highlight how methodological advances can guide public health stakeholders analysing societal discourses and seeking to convey medical information to the broader population."

Journal • Developmental Disorders • Infectious Disease • Novel Coronavirus Disease

From controversy to confidence: Strengthening dengue vaccines safety reporting. (PubMed, Vaccine) - "Dengue vaccines-Dengvaxia, Qdenga, and TV003/TV005 (NIH dengue vaccine) -offer potential for control, yet their implementation has been challenged by safety issues, including heightened risks in seronegative individuals, presumably due to antibody-dependent enhancement, though the precise mechanisms remain under investigation...The erosion of public trust following past vaccine controversies highlights the urgent need for transparency to bolster acceptance and inform policy. By integrating advanced surveillance with international cooperation, these measures can refine risk-benefit assessments, rebuild confidence in immunization programs, and maximize the protective impact of dengue vaccines, ultimately reducing the burden on vulnerable populations worldwide."

Journal • Dengue Fever

Flavivirus vaccines overview and lesions from Dengvaxia, the firstlicensed dengue vaccine (ASM Microbe 2025) - "There is no abstract associated with this presentation."

Dengue Fever

Dengue Vaccine Development and Deployment into Routine Immunization. (PubMed, Vaccines (Basel)) - "Despite decades of research, only two dengue vaccines-CYD-TDV (Dengvaxia) and TAK-003 (Qdenga)-have been licensed to date, with limited implementation...While future vaccines, including mRNA and virus-like particle candidates, are under development, optimizing the use of currently available vaccines is crucial to reducing dengue's public health impact. Given the continued rise in cases, immediate action-combining vaccination with vector control-is essential to prevent further morbidity and mortality."

Journal • Review • Dengue Fever

Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue. (PubMed, Vaccines (Basel)) - "Recently, a second licensed dengue vaccine, Qdenga®,Takeda, Singen, Germany), was approved and recommended by the WHO to be administered only in highly dengue-endemic countries, as it was not shown to elicit a robust immune response against DENV-3 and DENV-4 serotypes in dengue seronegative individuals. This review provides current insights to guide the development of a novel live-attenuated tetravalent dengue vaccine candidate that is effective against all DENV serotypes and safe from ADE. The efficacy and safety of the live-attenuated vaccine candidate should be further validated in in vivo studies."

Journal • Review • Dengue Fever • Infectious Disease

Rebuilding Public Trust: Factors Influencing Dengue Vaccine Uptake in the Aftermath of the Dengvaxia Controversy in the Philippines: A Partial Least Structural Equation Modeling Approach. (PubMed, Vaccine) - "While the study offers valuable insights, it acknowledges limitations in sample diversity and the exclusion of certain mediating factors, such as cultural and socio-economic variables. These findings contribute to the theoretical understanding of vaccine adoption and provide practical recommendations for designing effective public health interventions to address vaccine hesitancy and improve adoption rates."

Journal • Dengue Fever

Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: Final results of a 5-year case-control study. (PubMed, Vaccine) - "A single dose of CYD-TDV conferred extended protection against more severe presentations of dengue. The study is limited by an absence of baseline dengue serostatus of the participants prior to vaccination but a large majority in this this cohort were likely dengue seropositive."

Journal • Dengue Fever

The Genetic Evolution of DENV2 in the French Territories of the Americas: A Retrospective Study from the 2000s to the 2024 Epidemic, Including a Comparison of Amino Acid Changes with Vaccine Strains. (PubMed, Vaccines (Basel)) - "Overall, these findings provide a current overview of the genomic evolution of DENV2 in the FTA, which is crucial for developing more effective prevention and control strategies and for selecting future vaccines tailored to circulating strains."

Journal • Retrospective data • Dengue Fever

Unveiling the complexity of vaccine hesitancy: A narrative review focusing on dengue vaccination. (PubMed, Hum Vaccin Immunother) - "Key determinants included population characteristics, concerns about efficacy and safety, among others. A comprehensive understanding of these factors is essential to improve vaccine acceptance, support dengue prevention efforts, and ensure public health success."

Journal • Review • Dengue Fever

Knowledge-based mitigation of the environmental risk of Orthoflavivirus live-attenuated vaccines by targeting viral encoded determinants for the mosquito attenuated phenotype. (PubMed, Vaccine) - "The mosquito-attenuated phenotype also ensures the safety of the licensed LAVs IMOJEV, Dengvaxia and QDENGA...This review discusses knowledge of orthoflaviviral encoded determinants for infection and dissemination in mosquito tissues which have potential utility for the rational design of candidate LAVs. Several attenuating mutations discovered to date are located within genomic regions that are conserved among orthoflaviviruses and can potentially support the establishment of a broadly effective attenuating strategy."

Journal • Review • CNS Disorders • Infectious Disease